BPC-157 Dosage Chart by Weight: What Studies Actually Used

What Does a BPC-157 Dosage Chart by Weight Show?

No published BPC-157 dosage chart by weight exists for people. Doses per kilogram (kg) of body weight appear in animal studies. One small human study also used them. It gave BPC-157 as an enema, a liquid put into the rectum. That study was only written up as short meeting summaries.

BPC-157 is a peptide, a short chain of amino acids, first found in human stomach juice Jozwiak et al. 2025. This page sets out each per-kg dose a named source reports, in that source's own terms. It names the species, the route and how long dosing lasted. No study has shown that any of these doses is right for a person.

This content is for educational purposes only and is not medical advice. These compounds are intended for research use. A qualified clinician can advise on any health decision.

A microgram (mcg) is one thousandth of a milligram (mg). A placebo is a dummy treatment. The animal doses come from a lab study of how the body handles the peptide. They were not tested as treatments in people.

Where Do the BPC-157 Dosage by Weight Figures Come From?

The animal BPC-157 dosage by weight figures come from one study of how the body handles the drug. He et al. 2022 measured how fast rats and beagle dogs take up and clear BPC-157. Their team planned human trials for severe trauma and burns in China.

The paper names a proposed clinical dose of 200 mcg per person per day. The authors converted it to 20 mcg per kg for rats and 6 mcg per kg for dogs. The conversion used body surface area, not body weight alone. The same paper says earlier work found 6 to 50 mcg per kg effective in mice, rats and rabbits.

That 200 mcg figure is a proposal for a trial. The paper reports no human dosing, and no result for that dose in people. In rats and dogs, the half-life was under 30 minutes. Half-life is the time it takes for half the drug to leave the blood.

We found no primary source that sets a human dose range per kg of body weight. Our BPC-157 dosing protocol page covers the human doses reported in published studies.

Is There a Human BPC-157 Dosage by Body Weight?

Only one human BPC-157 dosage by body weight is on record. It is the Veljaca enema study in the table above. The FDA sums it up in a 2026 briefing document for its advisory panel.

The authors reported no significant side effects linked to treatment. Headache and flatulence were most common, with no clear difference from placebo. Blood levels of BPC-157 were mostly too low to measure.

The FDA lists five clinical studies in all. Two were enema studies that compared it with a placebo. Both were only written up as meeting abstracts. The other human doses on record are flat amounts per person, not per kg. The FDA said these studies "were of short duration" and "had small sample sizes." The FDA's conclusion was that "there is insufficient clinical safety information to characterize the safety profile" of BPC-157.

A 2025 systematic review found the same gap. That is a review that searches the research in a set, planned way. It found 544 articles from 1993 to 2024. Once copies were taken out, it kept 36 studies. Of those, 35 were preclinical, meaning animal or cell work. Just 1 was clinical, meaning done in people. It describes itself as a review of level IV and level V studies, which are low grades of evidence. It found no clinical safety data Vasireddi et al. 2025.

One human report gave BPC-157 into the knee joint. It was a look back at clinic records, with no control group. Of 16 patients reached by phone, 12 had BPC-157 alone and 4 had it with thymosin beta-4 (TB4), another peptide. In all, 14 of 16 reported relief of knee pain Lee et al. 2021.

A critical review of tendon and muscle healing found the animal results were consistently positive. Most studies used small rodents, and the effect is yet to be confirmed in humans Gwyer et al. 2019.

Is BPC 157 Peptide Dosage by Weight Backed by Safety Data?

The BPC 157 peptide dosage by weight data on safety is almost all from animals. Xu et al. 2020 tested BPC-157 in rodents (mice and rats), rabbits and dogs. A single large dose caused no effects linked to the peptide. Per the FDA's review, that dose was 20 mg per kg into a muscle in rats and 10 mg per kg in dogs.

With 28 days of daily dosing in dogs, creatinine fell. Creatinine is a blood marker of kidney function. The authors' abstract reports this at 2 mg per kg. The FDA's review reports it in female dogs at 2 mg per kg, and in male dogs at 0.5 mg per kg and above. The dogs recovered by the end of a 2-week recovery period after dosing stopped.

A 2025 review of papers and patents says BPC-157 has a desirable safety profile. Only a few side effects have been reported. It also says the FDA and other global regulators have not approved it for standard medicine. The reason it gives is too few clinical studies in humans Jozwiak et al. 2025.

The 2025 systematic review says the studies it included suggest BPC-157 boosts pathways involved in growing new blood vessels. That growth is called angiogenesis. No source we read tested BPC-157 in people with cancer, on blood thinners or on diabetes drugs. The same review warns of possible harm from unregulated manufacturing or contamination Vasireddi et al. 2025.

We keep a vendor-neutral breakdown on our sources page. Our page on whether BPC-157 is banned by WADA covers its status in sport.

References

• Vasireddi et al. 2025, "Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review," HSS J. PubMed
• Jozwiak et al. 2025, "Multifunctionality and Possible Medical Application of the BPC 157 Peptide," Pharmaceuticals (Basel). PubMed
• Gwyer et al. 2019, "Gastric pentadecapeptide body protection compound BPC 157 and its role in accelerating musculoskeletal soft tissue healing," Cell Tissue Res. PubMed
• Lee et al. 2021, "Intra-Articular Injection of BPC 157 for Multiple Types of Knee Pain," Altern Ther Health Med. PubMed
• He et al. 2022, "Pharmacokinetics, distribution, metabolism, and excretion of body-protective compound 157, a potential drug for treating various wounds, in rats and dogs," Front Pharmacol. PubMed
• Xu et al. 2020, "Preclinical safety evaluation of body protective compound-157, a potential drug for treating various wounds," Regul Toxicol Pharmacol. PubMed
• US Food and Drug Administration 2026, "BPC-157" briefing document, Pharmacy Compounding Advisory Committee, 23-24 July 2026. FDA

This content is for educational purposes only. These compounds are intended for research use. Nothing here is medical advice. A qualified clinician can advise on any health decision.